Hanmi First Korean Firm To Follow U.S. FDA 505(b)(2) Pathway; AstraZeneca Files Suit For Nexium
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Hoping to become the first Korean pharmaceutical company to sell modified generics in the U.S., Korea's Hanmi Pharmaceutical filed for U.S. FDA approval for the sale of Esomezol, its modified generic of AstraZeneca's Nexium (esomeprazole), but must first overcome a patent infringement lawsuit
You may also be interested in...
Korea's Green Cross Sees Earnings Plunge As Flu Fears Wane
SEOUL - As widely expected, vaccine producer Green Cross, one of Korea's leading pharmas, has seen a sharp drop in its sales and net profit during the fourth quarter of last year
Korea's Hanmi And Merck in Discussion to Sell Hanmi's Hypertension Drug In Other Countries including Six Asia-Pacific Countries
SEOUL - South Korea's Hanmi Pharmaceutical and MSD are pushing to sell Hanmi's incrementally modified hypertensive amlodipine product Amosartan in other countries includng six Asia-Pacific countries under Merck's brand Cozzar XQ
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
Need a specific report? 1000+ reports available
Buy Reports